Recently, IBFB-211913 (structure unavailable) was claimed as a new PDE4/7 inhibitor. It is reported under development for the treatment of asthma, autoimmune diseases and psoriasis . Future data related to this compound will be helpful to assess and understand the intrinsic contribution of the PDE7 inhibition toward efficacy and side effects. In relation to this topic, several patents claimed the use of dual inhibitors (PDE7/PDE4) to synergize pharmacological effects and to increase the therapeutic index [32,33]. A series of phthalazinones have been disclosed as dual
PDE7/4 inhibitor . The most potent example cited is compound 24, which is 23fold less active against PDE7 than PDE4.
Was this article helpful?
If you suffer with asthma, you will no doubt be familiar with the uncomfortable sensations as your bronchial tubes begin to narrow and your muscles around them start to tighten. A sticky mucus known as phlegm begins to produce and increase within your bronchial tubes and you begin to wheeze, cough and struggle to breathe.